drugset / Trial / NCT02684799
Pharmacokinetic and Safety Study of Cenicriviroc and Acid Reducing Agents When Dosed Alone or in Combination
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a Phase 1, Single and Multiple-Dose, Open-Label Study in Healthy Subjects to Assess the Effect of the Acid Reducing Agents, Omeprazole and Famotidine, on the PK of CVC
Timeline
- Start
- 2016-01-31
- Primary completion
- 2016-04-11
- Completion
- 2016-04-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cenicriviroc | Small molecule | 150 mg | — |
| Comparator | Famotidine | Other / unclassified | 40 mg | — |
| Comparator | Omeprazole | Other / unclassified | 40 mg | — |
Indications
No indication recorded.